Features of anticoagulant therapy of atrial fibrillation in combination with impaired renal function
| Autor: | T N Novikova |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Rivaroxaban
Kidney medicine.medical_specialty Pyridones business.industry medicine.drug_class Anticoagulant Warfarin Administration Oral Anticoagulants Renal function Atrial fibrillation medicine.disease Dabigatran medicine.anatomical_structure Internal medicine Atrial Fibrillation Humans Medicine Cardiology and Cardiovascular Medicine business Stroke medicine.drug Kidney disease |
| Zdroj: | Kardiologiia. 61:81-88 |
| ISSN: | 2412-5660 0022-9040 |
| DOI: | 10.18087/cardio.2021.10.n1767 |
| Popis: | This review focuses on issues of anticoagulant therapy in patients with atrial fibrillation (AF) associated with chronic kidney disease (CKD). Such patients are at high risk of stroke whereas the choice of an anticoagulant is difficult. A wealth of information about a negative effect of warfarin on the kidney function has accumulated. A need for an alternative therapy to warfarin for patients with stage 3-4 CKD has become imminent. In this regard, rivaroxaban seems to be an appropriate replacement for warfarin in such patients. In randomized, controlled studies that evaluated the efficacy of direct oral anticoagulants in comparison with warfarin, the efficacy and safety profile of a “kidney” dose in moderate disorders of kidney function has been studied only for rivaroxaban. Moreover, both randomized, controlled studies and studies performed in the conditions of clinical practice, have demonstrated a more favorable effect of rivaroxaban on kidney function compared to warfarin. Patients with AF associated with CKD require a comprehensive protection, which, according to results of clinical studies, may be provided by rivaroxaban. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|